Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Warsaw – page 118

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Warsaw at a glance
1 804
clinical trials
  • Research sites33
Type of trial
Recruitment status
Quick filters

1 804 trials in Warsaw

Open in trial search

Squamous cell carcinoma of lung

Not recruiting

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Squamous cell carcinoma of lung+3

Not recruiting

Study Comparing Subcutaneous and Intravenous Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Spinal muscular atrophy

Not recruiting

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Switching from Daily Basal Insulin to Weekly Insulin Icodec Compared to Daily Insulin Glargine in Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Immunoglobulin G4 related disease

Not recruiting

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Small cell lung cancer extensive stage

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Transitional cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Coeliac disease

Not recruiting

Study on the Effects of KAN-101 and Sodium Chloride in Adults with Celiac Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Kan-101
  • Sponsor:Kanyos Bio Inc.

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

  • RSV Prevention Studies
  • Influenza Vaccine Research
  • Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

  • Pediatric Vaccine Development
  • Immunogenicity Assessment
  • Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

  • Plaque Psoriasis Treatment
  • Biomarker Analysis
  • Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

  • Immunotherapy Research
  • Cancer Treatment Combinations
  • Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.